Ashland ASH Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Intermediates And Solvents | $35M+12.9% | $31M-6.1% | $33M0.0% | $33M-10.8% | $37M+12.1% | |
| Life Sciences | $172M+23.7% | $139M-19.7% | $173M+6.8% | $162M-5.8% | $172M+28.4% | |
| Personal Care And Household | $150M+22.0% | $123M-18.5% | $151M+2.7% | $147M+0.7% | $146M+9.0% | |
| Specialty Additives | $134M+31.4% | $102M-22.1% | $131M0.0% | $131M-2.2% | $134M+16.5% | |
| Cost Of Revenue by Business | ||||||
| Intermediates And Solvents | $29M0.0% | $29M— | —— | —— | $37M+32.1% | |
| Life Sciences | $109M+16.0% | $94M— | —— | —— | $117M+28.6% | |
| Personal Care And Household | $88M+11.4% | $79M— | —— | —— | $82M-5.7% | |
| Specialty Additives | $118M+34.1% | $88M— | —— | —— | $106M+7.1% | |
| Income Loss On Divestitutres Net by Business | ||||||
| Intermediates And Solvents | $0— | $0— | —— | —— | $0— | |
| Life Sciences | $0— | $0— | —— | —— | $0— | |
| Personal Care And Household | $0— | $0— | —— | —— | $0— | |
| Specialty Additives | $0— | $0— | —— | —— | $0— | |
| Unallocated And Other | -$0-100% | $2M— | —— | —— | $18M+110% | |
| Operating Income by Business | ||||||
| Intermediates And Solvents | $4M— | $0-100% | $2M-50.0% | $4M+500% | -$1M-133% | |
| Life Sciences | $35M+106% | $17M— | —— | -$343M-1,325% | $28M+100% | |
| Personal Care And Household | $27M+145% | $11M-57.7% | $26M+4.0% | $25M-10.7% | $28M+155% | |
| Specialty Additives | -$7M+12.5% | -$8M— | $0+100% | -$345M-5,029% | $7M+240% | |
| Unallocated And Other | -$20M+23.1% | -$26M-136% | -$11M+77.6% | -$49M-345% | -$11M+94.6% | |
| Selling General And Administrative Expense by Business | ||||||
| Intermediates And Solvents | $2M0.0% | $2M— | —— | —— | $1M-50.0% | |
| Life Sciences | $20M0.0% | $20M— | —— | —— | $19M-5.0% | |
| Personal Care And Household | $21M+5.0% | $20M— | —— | —— | $21M0.0% | |
| Specialty Additives | $17M+6.3% | $16M— | —— | —— | $15M-6.3% | |
| Unallocated And Other | $19M-32.1% | $28M— | —— | —— | $29M+52.6% | |
| Earnings Before Interest Tax Depreciation And Amortization by Business | ||||||
| Intermediates And Solvents | $5M+400% | $1M-80.0% | $5M-28.6% | $7M+250% | $2M-66.7% | |
| Life Sciences | $49M+58.1% | $31M— | —— | -$321M-694% | $54M+92.9% | |
| Personal Care And Household | $42M+61.5% | $26M-38.1% | $42M+5.0% | $40M-7.0% | $43M+48.3% | |
| Specialty Additives | $8M-20.0% | $10M— | $0+100% | -$309M-1,443% | $23M+109% | |
| Unallocated And Other | -$20M+23.1% | -$26M-136% | -$11M+77.6% | -$49M-345% | -$11M+94.6% | |
| Total Assets by Business | ||||||
| Intermediates And Solvents | $107M-2.7% | $110M-5.2% | $116M-1.7% | $118M-0.8% | $119M-4.0% | |
| Life Sciences | $1.46B-0.5% | $1.46B-2.4% | $1.5B-2.2% | $1.53B-18.4% | $1.88B+3.3% | |
| Personal Care And Household | $714M-1.2% | $723M-3.7% | $751M+7.4% | $699M-0.4% | $702M-2.1% | |
| Specialty Additives | $988M-0.2% | $990M-2.9% | $1.02B-2.7% | $1.05B-22.7% | $1.36B+2.4% | |
| Unallocated And Other | $1.24B+0.1% | $1.23B+0.7% | $1.23B+0.1% | $1.23B+3.7% | $1.18B-5.6% | |
| Research And Development Expense by Business | ||||||
| Intermediates And Solvents | $0— | $0— | —— | —— | $0— | |
| Life Sciences | $3M-25.0% | $4M— | —— | —— | $4M0.0% | |
| Personal Care And Household | $6M+20.0% | $5M— | —— | —— | $7M+16.7% | |
| Specialty Additives | $4M+33.3% | $3M— | —— | —— | $3M0.0% | |
| Unallocated And Other | $1M0.0% | $1M— | —— | —— | $0— | |
| Income Loss From Equity Method Investments And Other Income Expense by Business | ||||||
| Intermediates And Solvents | $0— | $0— | —— | —— | $0— | |
| Life Sciences | $0— | $0— | —— | —— | $0— | |
| Personal Care And Household | $0-100% | $1M— | —— | —— | $0-100% | |
| Specialty Additives | $0— | $0— | —— | —— | $0— | |
| Unallocated And Other | $0— | $0— | —— | —— | $0— | |
| PP&E (Net) by Business | ||||||
| Intermediates And Solvents | $30M0.0% | $30M0.0% | $30M— | —— | —— | |
| Life Sciences | $468M-1.9% | $477M-0.8% | $481M— | —— | —— | |
| Personal Care And Household | $95M-2.1% | $97M-4.0% | $101M— | —— | —— | |
| Specialty Additives | $468M-1.1% | $473M-2.3% | $484M— | —— | —— | |
| Unallocated And Other | $102M-1.9% | $104M-1.0% | $105M— | —— | —— | |
| Adjustment For Amortization by Business | ||||||
| Intermediates And Solvents | $0— | $0-100% | $1M— | $0— | $0— | |
| Life Sciences | $5M0.0% | $5M0.0% | $5M0.0% | $5M+25.0% | $4M-20.0% | |
| Personal Care And Household | $8M0.0% | $8M-11.1% | $9M+12.5% | $8M0.0% | $8M-20.0% | |
| Specialty Additives | $2M0.0% | $2M0.0% | $2M0.0% | $2M-33.3% | $3M+50.0% | |
| Unallocated And Other | $0— | $0— | —— | —— | $0— | |
| Depreciation by Business | ||||||
| Intermediates And Solvents | $1M0.0% | $1M-66.7% | $3M0.0% | $3M0.0% | $3M0.0% | |
| Life Sciences | $9M0.0% | $9M0.0% | $9M-47.1% | $17M-22.7% | $22M+144% | |
| Personal Care And Household | $7M0.0% | $7M0.0% | $7M0.0% | $7M0.0% | $7M-12.5% | |
| Specialty Additives | $13M-18.8% | $16M+6.7% | $15M-55.9% | $34M+162% | $13M-7.1% | |
| Unallocated And Other | $0— | $0— | —— | —— | $0— | |
| Goodwill by Business | ||||||
| Life Sciences | $462M-1.1% | $467M+0.2% | $466M0.0% | $466M-42.3% | $807M+1.8% | |
| Specialty Additives | $112M-0.9% | $113M+0.9% | $112M0.0% | $112M-73.7% | $426M+2.2% | |
| Goodwill Impaired Accumulated Impairment Loss by Business | ||||||
| Life Sciences | $375M0.0% | $375M0.0% | $375M0.0% | $375M— | —— | |
| Specialty Additives | $505M0.0% | $505M0.0% | $505M0.0% | $505M+190% | $174M0.0% | |
| Goodwill Foreign Currency Translation Gain Loss by Business | ||||||
| Life Sciences | -$5M-600% | $1M— | —— | $34M— | —— | |
| Specialty Additives | -$1M-200% | $1M— | —— | $17M— | —— | |
| Concentration Risk % by Product | ||||||
| Cellulosics And Polyvinylpyrrolidones | 64%-1.0pp | 65%— | —— | 65%+2.0pp | 63%0.0pp | |
| Cellulosics | 41%+2.0pp | 39%— | —— | 40%+2.0pp | 38%0.0pp | |
| Polyvinylpyrrolidones | 23%-3.0pp | 26%— | —— | 25%0.0pp | 25%0.0pp | |
| Revenue by Geography | ||||||
| Asia Pacific | $125M+13.6% | $110M-12.0% | $125M+5.9% | $118M-1.7% | $120M+5.3% | |
| Europe | $180M+36.4% | $132M-22.8% | $171M-2.8% | $176M-3.3% | $182M+35.8% | |
| Latin America And Other | $48M+17.1% | $41M-25.5% | $55M+22.2% | $45M0.0% | $45M+7.1% | |
| North America | $138M+23.2% | $112M-18.2% | $137M+2.2% | $134M-5.6% | $142M+12.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ashland break its business down?
- Ashland (ASH) reports revenue by business across 4 parts — Intermediates And Solvents, Life Sciences, Personal Care And Household and Specialty Additives. Each is extracted from the segment footnotes and tracked over time.
- Where does Ashland's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ashland's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
